Related Experiment Videos
T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms
1Division of Molecular Immunology, National Institute for Medical Research, London, United Kingdom.
Advances in Immunology
|January 26, 1999
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Th17-cell plasticity in Helicobacter hepaticus-induced intestinal inflammation.
Mucosal immunology·2013
Lineage fate alteration of thymocytes developing in an MHC environment containing MHC/peptide ligands with antagonist properties.
European journal of immunology·2001
Differential survival of naive CD4 and CD8 T cells.
Journal of immunology (Baltimore, Md. : 1950)·2000
Triggering a second T cell receptor on diabetogenic T cells can prevent induction of diabetes.
The Journal of experimental medicine·1999
Microbiome based diagnostic approaches.
Advances in immunology·2026
Microbiome as prognostic indicator in oral cancer.
Advances in immunology·2026
The role of the oral microbiome in oral cancer (OSCC).
Advances in immunology·2026
Oral squamous cell carcinoma (OSCC): An overview.
Advances in immunology·2026
Challenges and future directions in head and neck microbiome research.
Advances in immunology·2026
Artificial intelligence in microbiome data analysis: Applications in head and neck cancer.
Advances in immunology·2026
ASO Editorial: Lymph Node Dissection in the Immunotherapy Era: Friend or Foe?
Annals of surgical oncology·2026
[Analysis of clinicopathological and immunological characteristics of patients with acquired immune deficiency syndrome-associated diffuse large B-cell lymphoma complicated by Talaromyces marneffei infection].
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026
Real-World Experience With TRBC1 Immunohistochemistry Across Cutaneous T-Cell Lymphoma Subtypes:A Large Cohort Study.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026